 Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 GLOBE NEWSWIRE Gilead Sciences, Inc. Nasdaq: GILD and Jounce Therapeutics, Inc. Nasdaq: JNCE amended their existing license agreement for GS-1811 formerly JTX-1811, enabling Gilead ... The post Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jou... 